CardioDx abandons IPO plans; AltheaDx eyes $69M IPO; Assurex Health ropes in $30M for neuropsychiatric pharmacogenomics products;

> CardioDx nixed its plans for an IPO, citing unfavorable market conditions. More

> Molecular diagnostics outfit AltheaDx filed plans for a $69 million initial public offering. Story (reg. req.)

> Mental health pharmacogenomics company Assurex Health raked in $30 million to support development of its GeneSight neuropsychiatric products. Story

> Exact Sciences' ($EXAS) shares bounced back on Monday after the Centers for Medicare and Medicaid Services said that it made an error in the 2015 clinical lab fee schedule for the company's Cologuard test. More (reg. req.)

> VolitionRx is launching a clinical study at the University of Bonn in Germany to evaluate its lung cancer diagnostic platform. More

> CardioDx closed a $35 million financing round to support development of its genomic tests for coronary artery disease. More

And Finally… Proove Biosciences inked an exclusive licensing agreement with the University of North Carolina at Chapel Hill's School of Dentistry to incorporate its research on the genetics of pain perception into its diagnostic tests. More (reg. req.)

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.